Despite earlier positive Phase 2 results (statistically significant increase in total follicle count vs placebo), Biosplice discontinued the dalosirvat (SM04554) hair-loss program following completion of Phase 3, per secondary sources.
How it works
Topical small molecule designed to stimulate the Wnt signalling pathway, which plays a role in hair follicle formation and cycling.
Results so far
Phase 2: statistically significant increase in total hair follicle count vs placebo (no exact number captured). Phase 3 outcome not detailed in sources reviewed, but program was discontinued.
What's next
N/A — discontinued.
In India
No India-specific development identified.
Sources
- News report ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil and, for men, finasteride.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.